Skip to main content
OpenTrials
Completed

NCT Number: NCT02812797

Prognostic Value of Adipokine Levels of Patients With Chronic Heart Failure

The purpose of this study is to determine whether expressions of adipokines can provide prognostic information concerning patients with chronic heart failure.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Chronic Heart Failure

Age range

12 year–80 year

Sex eligibility

All sexes

Study type

Observational

Primary location

The First Affiliated Hospital of Chongqing Medical University

Chongqing, Chongqing Municipality, 400000, China

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Patients who are giving open chest surgical treatment with a history of chronic heart failure (NYHA II ~ IV) more than 6 months.
  • Patients from whom informed consent has been properly obtained in writing prior to start of the trial.

Exclusion criteria

  • Patients with concurrent infection or any documented inflammatory illness, such as arthritis or connective tissue diseases,or any other malignancy.
  • Patients with a history of cardiomyopathy.
  • Patients with Chronic arrhythmia.
  • Pregnant women
  • Severe hepatic dysfunction or End-stage renal failure.
  • Uncontrolled hypertension.

Treatment and study plan

Primary outcomes

  1. All-cause mortality

    Time frame: Change from Baseline at 3, 6 and 12 months

Secondary outcomes

  1. New York Heart Association (NYHA) Classification

    Time frame: Week:4

  2. re-hospitalization

    Time frame: Change from Baseline at 3, 6 and 12 months

    Heart failure with re-hospitalization is documented by at least one of the following: worse exercise tolerance and respiratory distress with NYHA class III or IV symptoms, presence of pulmonary rales, or chest radiography showing pulmonary congestion, which needs an augmented decongestive regimen with oral or intravenous medications during an in-hospital stay.

  3. plasma brain natriuretic peptide (BNP) concentration

    Time frame: Week:4

  4. Cardiovascular death

    Time frame: Change from Baseline at 3, 6 and 12 months

  5. Cardiac transplantation

    Time frame: Change from Baseline at 3, 6 and 12 months

Sponsors and collaborators

Lead sponsor

Chongqing Medical University

Other

Registry information

Important dates

Study start
2016
Primary completion
2019
Study completion
2020
First posted
Jun 24, 2016
Registry last updated
Mar 4, 2020

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.